Enhancing Children’s Lives with Biomarkers for Risk Stratification and Triage

BIOECLOSION S.L.

MAIN GOAL

To develop and validate a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and enhance child survival

 

EChiLiBRiST – Enhancing Children’s Lives with Biomarkers for Risk Stratification and Triage, is a consortium of 13 institutions from Europe, Africa and North America convened to develop and clinically validate a quantitative point-of-care test for the measurement of severity biomarkers to improve risk stratification of fever syndromes and thus, enhance child survival.

This five year project is funded by the European Union’s Horizon Europe research and innovation programme. The project consists of two distinct yet complementary workstreams – 1) Design and validation of the device and establishing the exploitation and regulatory pathways; 2) Clinical trials and sub-studies in 3 African countries to assess the impact of the introduction of the device for risk stratification purposes, to enhance outcomes, guide management, and save costs.

Funding program

Project funded under the European Union’s Horizon Europe research and innovation programme under the HORIZON-HLTH-2021-DISEASE-04 call

Project reference

101057114

The consortium

The EChiLiBRiST consortium is led by ISGlobal and includes:

BioEclosion
Universitat Autònoma de Barcelona
Eurecat
Asphalion
Eberhard Karls Universitaet Tuebingen
Ospedale Pediatrico Bambino Gesù
Centro de Investigação em Saúde da Manhiça
Haramaya University
Centre de Recherches Médicales de Lambaréné
University Health Network
London School of Hygiene and Tropical Medicine
London School of Economics

Project website

Funded by

European Union’s Horizon Europe research and innovation programme. Awarded by European Commission – Horizon Europe.